TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05985707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
Study: NCT04676893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T
Study: NCT04738175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT06136351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: 90mg/m\^2 ivgtt, D0 of each 28-day cycle
Study: NCT05959317

Intervention type: OTHER
Group type: OTHER
Intervention: Pilates Exercises
Description: Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.

Intervention type: OTHER
Group type: OTHER
Intervention: Neural dynamic mobilization
Description: Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
Study: NCT06281977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Programed as dexmedetomidine on infusion pump.
Study: NCT06379633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In vivo exposure
Description: Exposure in vivo involves the confrontation with fear-evoking situations in real life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Virtual reality) exposure
Description: Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
Study: NCT05946161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health intervention to promote mental and sexual health of prostate cancer survivors
Description: An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
Study: NCT04965298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
Study: NCT04746664

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional counselling
Description: Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
Study: NCT05045716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.
Study: NCT04828707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio active device
Description: Nerivio neurostimulator of conditional pain modulation (CPM)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nerivio sham device
Description: Nerivio neurostimulator with an electrical output not intended for neurostimulation
Study: NCT06361966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printed prosthetic socket
Description: 3d printed prosthetic socket produced through multi-jet fusion (MJF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed prosthetic socket
Description: 3d printed prosthetic socket produced through multi-jet fusion (MJF)
Study: NCT05011149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent.
Study: NCT06230484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign first palatal expander
Description: Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rapid maxillary expansion
Description: Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
Study: NCT05249205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHIT1
Description: This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHIT2
Description: This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
Study: NCT06113003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Wheat dextrin fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic packet
Study: NCT05305898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation.
Study: NCT06551675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silkworm pupa tablets
Description: Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control product
Description: The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
Study: NCT04731896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: artificial rupture of the amniotic sac
Study: NCT05173805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-15293
Description: After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
Study: NCT04091191

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meta19.01
Description: A specialized nutraceutical containing plant extracts, vitamins and fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meta19.01
Description: A specialized nutraceutical containing plant extracts, vitamins and fish oil
Study: NCT05106686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aureobasidium pullulans produced β-glucan group
Description: Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Placebo 300 mg/day for 12 weeks
Study: NCT06062381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles.
Study: NCT05973708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamshell Exercise
Description: Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frog pump exercise
Description: Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
Study: NCT05266846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
Study: NCT06149832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
Study: NCT05190159

Intervention type: DEVICE
Intervention: Monster Screw System
Description: Subjects who have undergone a foot and/or ankle procedure involving the index device
Study: NCT05433493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant.
Study: NCT04376515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE intervention
Description: Online peer support community of peers trained in behavior change science
Study: NCT05007392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotinurad
Description: Dotinurad oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat oral tablets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dotinurad Matched Placebo
Description: Dotinurad matched placebo oral tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Febuxostat Matched Placebo
Description: Febuxostat matched placebo oral tablets.
Study: NCT05924516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Fatigue Digital Program
Description: The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
Study: NCT05129761

Intervention type: DRUG
Intervention: Syrup Hydryllin
Description: ( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
Study: NCT05943015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block II
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled intravenous analgesia
Description: Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block III
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
Study: NCT06292377

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echography (TTE)
Description: A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
Study: NCT05137691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted NHS weight management 1:1 programme
Description: Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NHS 1:1 weight management programme
Description: NHS 1:1 weight management programme
Study: NCT05043181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Density Lipoprotein Receptor mRNA Exosomes
Description: The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase.
Study: NCT04342091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOL Nova Device
Description: A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
Study: NCT00716339

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivation
Study: NCT05034276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE-VR
Description: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
Study: NCT05303376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBIO123
Description: 5 or 10 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05134636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text triage
Description: The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
Study: NCT05943015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled intravenous analgesia
Description: Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
Study: NCT06443749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node